KHCM
IOVA icon

Kettle Hill Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Kettle Hill Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-41,906
Closed -$336K – 50
2024
Q2 		$336K Buy
+41,906
New +$449K 0.08% 47
2023
Q4 		– Sell
-38,474
Closed -$175K – 48
2023
Q3 		$175K Buy
+38,474
New +$251K 0.04% 37
2023
Q1 		– Sell
-96,007
Closed -$613K – 69
2022
Q4 		$613K Buy
+96,007
New +$750K 0.12% 43
2022
Q3 		– Sell
-81,958
Closed -$905K – 76
2022
Q2 		$905K Buy
+81,958
New +$1.07M 0.23% 45

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Kettle Hill Capital Management's IOVA Position: Q3 2024 in Review

Kettle Hill Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q3 2024, closing a stake of 41,906 shares — an estimated $336K sold.

Kettle Hill Capital Management first reported a position in IOVA in Q2 2022 and held it in 4 quarters. The position peaked at $905K in Q2 2022. 286 funds tracked by Wall St. Rank hold IOVA as of Q3 2024.

  • Kettle Hill Capital Management reported no remaining Iovance Biotherapeutics position as of Q3 2024 after selling out during the quarter.
  • Kettle Hill Capital Management sold 41,906 Iovance Biotherapeutics shares in Q3 2024, an estimated $336K.
  • Kettle Hill Capital Management first reported a position in Iovance Biotherapeutics in Q2 2022 and held it in 4 quarters.
  • Kettle Hill Capital Management's Iovance Biotherapeutics position peaked at $905K in Q2 2022.
  • 286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2024.

Based on Kettle Hill Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.